Q1 results, resolving litigation, but faces trade and NIH policy challenges. Click for my look at TXG stock prospects.

As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results ...

10x Genomics employed 584 workers worldwide at the end of 2019, 852 people at the end of 2020, 1,239 people at the end of 2021 and 1,243 at the end of 2022, the SEC filings showed.

Biotech company 10x Genomics (NASDAQ:TXG) will be reporting earnings tomorrow after market hours. Here’s what to look for. 10x Genomics missed analysts’ revenue expectations by 5% last quarter ...

Biotech company 10x Genomics (NASDAQ:TXG) will be announcing earnings results tomorrow after the bell. Here’s what investors should know. 10x Genomics beat analysts’ revenue expectations by 3. ...

10X Genomics, Inc. is a life science technology company, which engages in building products to interrogate, understand and master biology. Its integrated ...

Gene sequencing technology company 10x Genomics (TXG 0.56%) hasn't been having it easy in the past few days on the stock market. A bearish analyst move dampened sentiment on the company, and ...

10x Genomics will host a conference call to discuss its third quarter 2024 results, business developments and outlook after market close on Tuesday, October 29, 2024 at 1:30 PM Pacific Time / 4:30 ...

10x Genomics reported 18% YoY revenue growth in Q4, reaching $184M, with instruments revenue seeing a remarkable surge of 71%. Find out why TXG is poised for sustained growth.

Life-sciences technology startup 10x Genomics Inc. said its initial public offering was priced above the high end of the expected range, giving it a valuation topping $3.6 billion.

Genomics startup Parse Biosciences lost its bid to dismiss a patent-infringement lawsuit brought by rival 10x Genomics and Stanford University on Thursday, when a Delaware federal court denied ...